NOVO NORDISK A/S overview

Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain PR Newswire BOSTON, April 10, 2024 BOSTON , April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years. Novo Nordisk and Ginkgo have created a...

Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity PR Newswire PLAINSBORO, N.J., March 8, 2024 Wegovy ® (semaglutide) injection 2.4 mg is the first-and-only medicine indicated for both reduction of the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke and for long-term weight management 1 The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever...

Thinking about trading options or stock in Oracle, Cardinal Health, Hewlett Packard Enterprise, Novo Nordisk, or Victoria's Secret? PR Newswire NEW YORK, March 7, 2024 NEW YORK , March 7, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORCL, CAH, HPE, NVO, and VSCO. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report...

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023 PR Newswire COPENHAGEN, Denmark, March 6, 2024 COPENHAGEN, Denmark , March 6, 2024 /PRNewswire/ -- Focusing its support on science, education, innovation and development initiatives, the Foundation's overall ambition is to improve human and planetary health. In 2023, the Foundation awarded more than DKK 9.1 billion , in philanthropic grants and investments, and supported a total of 751 new...

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases PR Newswire SAN DIEGO, Feb. 26, 2024 Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO , Feb. 26, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a...

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases PR Newswire SAN DIEGO, Feb. 27, 2024 Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases Total potential deal value of $1.46B across multiple targets SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it has entered into a...